Rocket Labs 38% Collapse|Record Backlog Meets SpaceX Capital Drain

SpaceX Opened, Rocket Lab Fell

Rocket Lab shares fell 6.34% on June 25, pulling the stock to $95 from a high of $151 reached just weeks earlier. The surface explanation is a $3 billion at-the-market equity offering that investors fear will dilute their stakes. But the 38% correction started before that announcement — and the ATM is not the bottleneck. The real driver is a structural capital reallocation: SpaceX's historic IPO on June 12 absorbed space-sector investment dollars at a scale that left even record-breaking competitors starved of marginal buyers.

SpaceX traded $85 billion worth of shares on its first day alone, exceeding combined volume of the QQQ and SPY ETFs over the same period. That is not simply enthusiasm — it is capital that had been positioned in space proxies like RKLB now routing directly into the primary name. Retail investors bought more SpaceX in its first week than they bought of all seven Magnificent Seven stocks combined. Every dollar deployed into SpaceX at $135 on June 12 did not appear from nowhere. A meaningful portion rotated out of RKLB, which had been the space sector's listed proxy during SpaceX's private years.

The $3 billion ATM announcement then arrived into that already-depleted order book. When the marginal buyer has already left, dilution fear moves a stock far more than the same announcement would in a neutral capital environment. The provisional read is that RKLB's move from $151 to $95 is a valuation reset driven more by who left the room than by anything Rocket Lab did wrong.

Two Institutions, One Stock, Opposite Calls

The institutional read on Rocket Lab split sharply in Q1. BI Asset Management reduced its stake by 79.7%, offloading 122,417 shares and leaving only 31,259 remaining, valued near $2 million. In the same period, Vanguard Group expanded its RKLB position by 13.4%, adding 5.6 million shares. Both moves are grounded in the same Q1 earnings release, the same $2.2 billion backlog figure, the same forward guidance. Their conclusions are pointing in opposite directions.

Wells Fargo initiated coverage with an Equal Weight rating and a $60 price target — implying the stock is overvalued even at $95. Deutsche Bank, reviewing the same data, raised its target from $73 to $120 and maintained Buy. That is not a minor disagreement about discount rates. It reflects a fundamental split on whether RKLB's 67x forward price-to-sales ratio is justified by a defense-anchored recurring revenue model, or whether it is a space-sector valuation premium that SpaceX's IPO has now rendered obsolete.

The ATM program itself sits inside this disagreement. Management framed the $3 billion equity raise as positioning for organic growth and M&A execution — the same logic that brought in the Mynaric and Motiv acquisitions. Bears read it as proof that the company cannot fund its ambitions internally, that Neutron development burn requires perpetual dilution. The conflict between these readings is not resolvable from the Q1 press release alone. It requires knowing whether RKLB's defense contracts convert into the kind of recurring revenue that justifies the multiple — and that answer sits in the next earnings call.

Record Defense Wins, Stranded Valuation

Rocket Lab's Q1 2026 results were the best in its history. Revenue hit $200.3 million, up 63.5% year-over-year. Gross margin reached 38.2%. The company signed 31 new Electron and HASTE contracts in a single quarter — more launches booked in Q1 2026 than in all of 2025. Its total launch manifest exceeded 70 contracted missions. The backlog of $2.2 billion grew 20.2% quarter-over-quarter.

On June 25, the same week RKLB fell to $95, Rocket Lab completed the Victus Haze mission for the U.S. Space Force — building the satellite, launching it, and beginning operations within 16 hours and 42 minutes of receiving the order. That set a new record for the military's Tactically Responsive Space program. More significant than the $32 million contract value is what Victus Haze proved: Rocket Lab can serve as a prime contractor for complete defense missions, not merely a launch provider. The Pentagon is moving toward companies that build, launch, and operate systems under one roof. RKLB is now on that list alongside traditional primes.

Here is the buried assumption the consensus misses: analysts pricing RKLB at a 67x price-to-sales multiple are implicitly assuming the company remains a growth-stage launcher competing on volume. The Victus Haze mission and Golden Dome Space Based Interceptor selection — in partnership with Raytheon — represent a different business model entirely: recurring defense contracts with mission-critical classification that do not trade on the open market. The assumption that RKLB should compress to a launch-company multiple fails the moment it wins Pentagon recurring-contract revenue. CFO Adam Spice sold 62,744 shares at $142.57 in late May through a 10b5-1 plan — a scheduled transaction, not a conviction signal — yet the market read it as insider distribution at the top. That misread of a pre-planned sale as bearish intent is the kind of frame distortion that appears at price lows, not highs.

Neutron and the ETF Bid — What Resolves the Fork

Two forces are now in direct tension underneath RKLB's price. The first is the Nasdaq-100 inclusion that took effect this week. ETFs tracking the index — including products managed by Vanguard, BlackRock, and State Street — are required to hold RKLB in proportion to its index weight. That is mechanical demand that does not respond to sentiment. State Street just launched a new Nasdaq-100 ETF, QNDX, adding another passive buyer to the pool. The forced buying from index inclusion was expected to be the catalyst for RKLB — instead the stock fell to $100 on the day of inclusion, a classic sell-the-news event. That mechanical ETF bid is still present in the order book. It does not expire.

The second force is the Neutron medium-lift rocket, on which Rocket Lab has already signed five dedicated launch contracts. Neutron's revenue ramp is the variable that actually decides whether the Wells Fargo $60 thesis or the Deutsche Bank $120 thesis is correct. A launch-company multiple without Neutron revenue cannot support $120. A defense-prime multiple with Neutron operational changes the earnings trajectory entirely. The next earnings call will be the first chance to hear management quantify the Neutron timeline and the Golden Dome contract scope.

The counter-evidence that survives scrutiny: RKLB's net margin remains negative at -26.87%, and the company has not yet demonstrated free cash flow. The $3 billion ATM signals that profitability is not imminent. If the Fed raises rates later this year — nine FOMC members projected at least one hike — the discount rate applied to long-duration growth stories like RKLB rises further. That is the real bear case, and it does not depend on whether management is wrong about the strategy.

For a holder, the decision variable is whether the next earnings call confirms Neutron delivery timing and the Golden Dome scope expands beyond the initial Space Based Interceptor selection. For a watcher, the entry signal is the ETF forced buying stabilizing the $100 level. That support has held twice this week. If the $3 billion ATM is deployed into Neutron development and two new defense acquisitions close, the dilution reads differently in twelve months than it does today.